Evidence map›Paper›PMID 34019806›Full record

ArticleCancer cell2021

Conserved pan-cancer microenvironment subtypes predict response to immunotherapy.

Alexander Bagaev, Nikita Kotlov, Krystle Nomie, Viktor Svekolkin, Azamat Gafurov, Olga Isaeva, Nikita Osokin, Ivan Kozlov, Felix Frenkel, Olga Gancharova and 4 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06776198 (Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study), which is not on this map. Cited by 854 papers.

0numbers the graph read from it
0cells of the map it votes in
854citing papers in PubMed
89.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06776198 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study

Typeobservational_patient_registrySponsorPeking University People's HospitalRan2025 to 2027Enrolled100ConditionsOsteosarcoma, Transcriptome, Tumor Microenvironment, Precision MedicineArmsChemotherapy
3 · Its place in the literature

Who cites it

854 citing papers in PubMed, 1,250 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  13. Trial
  14. Biological effects ofEuropean radiology · 2026
    Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. A meta-interaction basis for cell-cell communication in tissues.bioRxiv : the preprint server for biology · 2026
    Article

794 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Alexander BagaevBostonGene, Waltham, MA 02453, USA.
Nikita KotlovBostonGene, Waltham, MA 02453, USA.
Krystle NomieBostonGene, Waltham, MA 02453, USA.
Viktor SvekolkinBostonGene, Waltham, MA 02453, USA.
Azamat GafurovBostonGene, Waltham, MA 02453, USA.
Olga IsaevaBostonGene, Waltham, MA 02453, USA.
Nikita OsokinBostonGene, Waltham, MA 02453, USA.
Ivan KozlovBostonGene, Waltham, MA 02453, USA.
Felix FrenkelBostonGene, Waltham, MA 02453, USA.
Olga GancharovaBostonGene, Waltham, MA 02453, USA.
Nava AlmogBostonGene, Waltham, MA 02453, USA.
Maria TsiperBostonGene, Waltham, MA 02453, USA.
Ravshan AtaullakhanovBostonGene, Waltham, MA 02453, USA. Electronic address: ravshan.ataullakhanov@bostongene.com.
Nathan FowlerBostonGene, Waltham, MA 02453, USA; Department of Lymphoma and Myeloma, Unit 0429, the University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: nfowler@mdanderson.org.
Addgene · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the complexity of tumors, including the tumor microenvironment (TME), a crucial mediator of cancer progression and therapeutic outcome. TME classification by transcriptomic analysis of >10,000 cancer patients identifies four distinct TME subtypes conserved across 20 different cancers. The TME subtypes correlate with patient response to immunotherapy in multiple cancers, with patients possessing immune-favorable TME subtypes benefiting the most from immunotherapy. Thus, the TME subtypes act as a generalized immunotherapy biomarker across many cancer types due to the inclusion of malignant and microenvironment components. A visual tool integrating transcriptomic and genomic data provides a global tumor portrait, describing the tumor framework, mutational load, immune composition, anti-tumor immunity, and immunosuppressive escape mechanisms. Integrative analyses plus visualization may aid in biomarker discovery and the personalization of therapeutic regimens.

Indexed as

Gene Expression Regulation, NeoplasticCancer-Associated FibroblastsDatabases, FactualData VisualizationGene Expression ProfilingHumansImmune Checkpoint InhibitorsImmunotherapyMelanomaNeoplasmsPrecision MedicineSkin NeoplasmsTreatment OutcomeTumor MicroenvironmentImmune Checkpoint Inhibitorsbiomarker discoverycancergenomicsintegrated analysistranscriptomicstumor microenvironment classification

Identifiers

PMID34019806
OpenAlexW3162215872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.